GLP-1 Receptor Agonist Market

GLP-1 Receptor Agonist Market Snapshot

Globally, nearly 463 Mn people between 20 and 70 years of age are estimated to be suffering from diabetes, as per the International Diabetes Federation in 2019.

Also, as per WHO, over 1.9 Mn adults were found to be overweight as of 2016. Obese and overweight people are at a greater risk of developing cardiovascular and gastric ailments and diabetes.

The GLP-1 receptor agonist market is influenced by an increase in the number of people categorized as obese or diagnosed as diabetics. A growth in these numbers is likely to push adoption of GLP-1 receptor agonists over the forecast period.

New Product Launches Remain Key to Growth

GLP-1 receptor agonist market players are tabling new products to gain a competitive advantage over one another. This trend is bound to drive the market in the forecast period.

For instance –

• In Jul 2020, 9 Meters Biopharma, started dosing NM-002 (long-acting GLP-1 receptor agonist), which has been designed especially for treating gastric motility by slowing down the digestive transit time
• In June 2020, Sun Pharmaceuticals announced an updation regarding its pre-clinical module. The experimental NCE (New Chemical Entity) comes across as a long-acting GLP-1R agonist for treating patients suffering from type 2 diabetes inclusive of long-acting, intermediate-acting, and short-acting therapies
• In Jun 2020, Pfizer showcased Phase I data from study assessing PF-06882961, a GLP-1R agonist in the patients contracting Type 2 Diabetes at the virtual American Diabetes Association meeting. The findings showed that this GLP-1 receptor agonist significantly reduced body weight and glucose levels in these patients
• In Jun 2020, Novo Nordisk tabled results from a real-world study – “PATHWAY” that extends support to recommendations in clinical guidelines by showcasing that initiating a GLP-1 receptor agonist does help people affected by type 2 diabetes in weight loss as well as reaching blood sugar levels.
• In Jun 2020, Novo Nordisk announced the approval of Rybelsus (oral semaglutide) (the sole oral GLP-1 R agonist in the form of a tablet) from the Japanese Ministry of Health, Labour and Welfare to treat people with type 2 diabetes
• In Apr 2020, AstraZeneca funded a clinical trial to evaluate usage of short-acting GLP-1 receptor agonists as one of the add-on treatments to insulin therapy in the type 1 diabetes.

GLP-1 Receptor Agonist Market: R&D Activities

As per researchers at the Icahn School of Medicine, beta cells could be regenerated at much higher rates by combining DYRK1A drugs with GLP-1 receptor agonists.

The GLP-1 receptor agonists could be any of the prescribed meds like Bydureon from AstraZeneca, Trulicity from Eli Lilly, Rybelsus, Ozempic, and Victoria from Novo Nordisk.

“Diabetes Care”, published study results stating that treatment with lixisenatide GLP-1 receptor agonist significantly slows gastric emptying and reduces postprandial glycaemia. In May 2017, “Diabetes, Obesity and Metabolism” published that the ones suffering from type 2 diabetes witnessed lower frequency of gastrointestinal events with a weekly dose of exenatide (a GLP-1 receptor agonist).

“The Lancet Diabetes & Endocrinology”, in Jan 2020, published that GLP-1 receptor agonists could be considered while going for future stroke prevention guidelines for those suffering from diabetes.

Also, in Sep 2019, researchers at the 55^th Annual Meeting of the European Association for the Study of Diabetes, reported that a new GLP-1 receptor agonist named “PEX168” showed positive results with respect to treatment of those suffering from type 2 diabetes

Covid-19 Impact on GLP-1 Receptor Agonist Market

The outbreak of Covid-19 has reduced the frequency of research and approvals for GLP-1 receptor agonists This scenario is expected to continue till the end of the year 2020. The normalcy is expected to get restored by the first quarter of the year 2021.

GLP-1 Receptor Agonist Market: Region-wise Analysis

Download a Comprehensive Report Snapshot

North America held more than 70% of market share in the year 2019. This could be attributed to the ever-increasing utilization of GLP-1 Receptor Agonists along with a well-established demand-supply chain consisting of pharmaceutical and biopharmaceutical industry.

Europe is the second largest market for GLP-1 receptor agonist, and the growing obesity rates in the region are likely to boost adoption over the forecast period. According to the WHO also states that around 60 million people all across the Europe are suffering from diabetes.

Asia Pacific is expected to grow at the fastest rate in the forecast period due to the fact that more than 70% of the global diabetic population resides in India and China. Also, 40.9% of the population is found to be obese (as per ADB Institute).

GLP-1 Receptor Agonist Market: Competition Landscape

The GLP-1 receptor agonist market players are adopting diverse strategies like geographic expansion and mergers and acquisitions (M&A) for gaining a strong foothold.

For instance – Sanofi, in Jan 2020, made an announcement of acquiring Synthorx, Inc. This acquisition is likely to help the company to lay its hands on genetic alphabet platform technology.

Research collaborations between the players for developing new products have also been moving towards market substantiation.

For instance – Boehringer Ingelheim and Eli Lilly and Company, in Dec 2018, collaborated with DCRI (Duke Clinical Research Institute) to develop GLP-1 Receptor Agonist for addressing cardiovascular ailments and diabetes.

In addition to Eli Lily and Company, and Sanofi, key players in the GLP-1 receptor agonist market include Novo Nordisk and AstraZeneca.

GLP-1 Receptor Agonist Market: The Way Forward

The GLP-1 Receptor Agonist Market is expected to be going strong, with FMI’s analysis predicting steady growth between 2020 and 2030. Research and innovative approaches are expected to drive the market in the near future.

The key market players need to look upon reaching out to wider geographies through inorganic expansion, so as to cater to a larger patient-base. Innovations are already on the anvil. They, coupled with mergers, acquisitions, partnerships, joint ventures will add to the competitive landscape

Key Segment

Drug Class

• Exenatide
• Liraglutide
• Dulaglutide
• Lixisenatide
• Others

Route of Administration

• Parenteral
• Oral

Distribution Channel

• Hospitals
• Clinics
• Ambulatory Surgical Centres

Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa